---

---

tags : Trial    crawled time : 22:00   

save search

---

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.5 3.31% 3.2% 7.4K |

Health Technology

| 3.38% | O: 4.43% H: 0.0% C: 0.0%
dm199 first stroke treatment for trial therapeutics

---

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
Published: 2024-04-09 (Crawled : 22:00) - globenewswire.com
ALXO M | $16.24 4.77% 4.56% 440K |

Commercial Services

| 31.44% | O: -2.59% H: 1.75% C: 0.25%
ongoing trial

---

Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
Published: 2024-04-03 (Crawled : 22:00) - biospace.com/
SNGX | $0.385 -3.75% -3.9% 490K |

Health Technology

| -29.63% | O: -0.33% H: 3.92% C: -9.85%
design trial agreement

---

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M |

Health Technology

| -8.24% | O: 0.26% H: 2.03% C: 1.57%
first disease active update trial

---

Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - prnewswire.com
FUSN | $21.4 -0.09% -0.09% 270K |

Health Technology

| 103.81% | O: 1.33% H: 2.16% C: -6.95%
fpi-2265 pharmaceuticals meeting trial

---

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
Published: 2024-02-29 (Crawled : 22:00) - prnewswire.com
RGNX | $16.05 0.94% 0.93% 350K |

Health Technology

| -8.03% | O: 2.41% H: 21.44% C: 18.65%
duchenne trial

---

Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Published: 2024-02-15 (Crawled : 22:00) - prnewswire.com
RNA | News M | $25.105 -0.14% -0.14% 560K |

Health Technology

| 85.44% | O: -0.59% H: 6.91% C: 5.43%
conference association trial living

---

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
Published: 2024-02-15 (Crawled : 22:00) - globenewswire.com
IVA | $3.28 -0.3% -0.3% 13K |

Health Technology

| -17.77% | O: -15.23% H: 6.88% C: -0.9%
year update trial financial

---

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
Published: 2024-02-08 (Crawled : 22:00) - biospace.com/
CVKD | $0.4242 -0.54% -0.54% 38K |

| -61.95% | O: -14.15% H: 2.05% C: -6.2%
trial therapeutics

---

LPSN DEADLINE TODAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages LivePerson, Inc. Investors with Losses to Secure Counsel Before Important January 30 Deadline in Securities Class Action - LPSN
Published: 2024-01-30 (Crawled : 22:00) - prnewswire.com
GDHG | $0.284 10.12% 9.19% 4.2M |

| -50.79% | O: 1.49% H: 10.06% C: 2.6%
LPSN S | $0.5034 1.68% 1.65% 2.3M |

Technology Services

| -82.53% | O: 1.03% H: 0.17% C: -5.08%
FTFT | $0.875 4.17% 4.0% 15K |

Consumer Non-Durables

| -16.5% | O: 1.94% H: 3.81% C: 0.0%
deadline trial

---

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K |

Health Technology

| -9.88% | O: -0.27% H: 0.07% C: -0.07%
EXEL | $23.7 1.76% 1.73% 1.5M |

Health Technology

| 7.24% | O: 0.14% H: 1.4% C: -0.23%
ntact-02 asco cancer trial results

---

Vanda Pharmaceuticals announces the publication of an article on The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| 15.54% | O: -1.0% H: 0.84% C: 0.04%
VNDA | $4.57 -1.3% -1.31% 1.5M |

Health Technology

| 24.25% | O: 2.72% H: 0.53% C: 0.53%
publication pharmaceuticals trial diabetic

---

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
Published: 2024-01-22 (Crawled : 22:00) - globenewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K |

Health Technology

| -10.55% | O: -0.14% H: 0.17% C: -0.27%
cabometyx asco immunotherapy trial

---

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
Published: 2024-01-18 (Crawled : 22:00) - globenewswire.com
AXGN | $6.875 -1.36% -1.38% 120K |

Health Technology

| -15.6% | O: 0.98% H: 7.06% C: 6.81%
positive topline trial results

---

Fortrea Establishes Industry Partnership with Veeva and Advarra to Streamline Patient and Site Clinical Trial Experience
Published: 2024-01-09 (Crawled : 22:00) - globenewswire.com
FTRE | $37.28 0.92% 0.91% 910K |

n/a

| 15.15% | O: -0.31% H: 0.0% C: -3.72%
VEEV | $200.52 -0.29% -0.26% 540K |

Technology Services

| 3.9% | O: 0.36% H: 0.82% C: 0.1%
partnership trial

---

Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
Published: 2024-01-05 (Crawled : 22:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M |

Health Technology

| 8.54% | O: 0.08% H: 0.29% C: 0.1%
merck pipeline trial

---

Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
Published: 2024-01-04 (Crawled : 22:00) - biospace.com/
RIGL | $1.125 -1.32% -1.33% 6.4M |

Health Technology

| -22.07% | O: 2.76% H: 2.68% C: 0.0%
collaboration trial

---

Stuart Therapeutics Announces First Patient, First Visit in its Phase 3 Clinical Trial of Vezocolmitide for Dry Eye Disease
Published: 2023-12-29 (Crawled : 22:00) - prnewswire.com
GKOS | $100.93 -0.17% 0.0% 520K |

Health Technology

| Email alert Add to watchlist
first disease eye trial therapeutics

---

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
Published: 2023-11-20 (Crawled : 22:00) - globenewswire.com
CNTB | $1.39 3.57% 41K |

Professional, Scientific, and T...

| -33.5% | O: 6.31% H: 2.28% C: -42.47%
dermatitis biopharma trial china

---

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Published: 2023-11-20 (Crawled : 22:00) - globenewswire.com
AVTE M | $21.27 -8.4% -9.17% 300K |

Professional, Scientific, and T...

| 46.11% | O: -1.79% H: 3.93% C: 1.75%
av-101 treatment hypertension trial therapeutics

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---